Skip to main navigation
Caribou Biosciences, Inc. Logo

Press releases

Date Title View
May 27, 2026
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
PDF Version
May 13, 2026
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
PDF Version
May 12, 2026
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
PDF Version
May 7, 2026
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
PDF Version
May 5, 2026
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
PDF Version
March 31, 2026
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
PDF Version
March 5, 2026
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
PDF Version
February 12, 2026
Caribou Biosciences to Participate in Upcoming Investor Conferences
PDF Version
February 4, 2026
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
PDF Version

Print page

Email alerts

RSS feeds

Investor contact

  • News & events
    • Press releases
    • Events
    • Presentations
  • Stock information
    • Stock quote & chart
    • Analyst coverage
  • Corporate governance
    • Policies & charters
    • Leadership
    • Board of Directors
    • Committee composition
  • Financials & filings
    • SEC filings
  • IR resources
    • FAQs
    • Email alerts
    • Contact IR
  • More
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Partnering
    • Technology
      • chRDNA technology
      • CAR-T cell therapy platform
      • Scientific publications
    • Pipeline
      • T cell pipeline
      • Clinical trials
      • Videos
    • Careers
      • Job opportunities
      • Values
      • Diversity and inclusion
      • Benefits
    • Investors
      • News & events
        • Press releases
        • Events
        • Presentations
      • Stock information
        • Stock quote & chart
        • Analyst coverage
      • Corporate governance
        • Policies & charters
        • Leadership
        • Board of Directors
        • Committee composition
      • Financials & filings
        • SEC filings
      • IR resources
        • FAQs
        • Email alerts
        • Contact IR
    • Contact
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Partnering
    • Technology
      • chRDNA technology
      • CAR-T cell therapy platform
      • Scientific publications
    • Pipeline
      • T cell pipeline
      • Clinical trials
      • Videos
    • Careers
      • Job opportunities
      • Values
      • Diversity and inclusion
      • Benefits
    • Investors
      • News & events
        • Press releases
        • Events
        • Presentations
      • Stock information
        • Stock quote & chart
        • Analyst coverage
      • Corporate governance
        • Policies & charters
        • Leadership
        • Board of Directors
        • Committee composition
      • Financials & filings
        • SEC filings
      • IR resources
        • FAQs
        • Email alerts
        • Contact IR
    • Contact

    Caribou Biosciences, Inc. Logo

    Caribou Biosciences, Inc.
    2929 7th Street, Suite 105
    Berkeley, CA 94710
    Tel: 510-982-6030

    © 2026 Caribou Biosciences, Inc. All rights reserved.
    • Privacy policy
    • Terms of use
    • Twitter
    • linkedin
    Website Design: Hane Chow, Inc .